3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gastrointestinal
1
Conditions
Neoplasms
4
Venous Thrombosis
2
Venous Thromboembolism
2
Colonic Neoplasms
2
Carcinoma, Hepatocellular
2
Thrombosis
1
Thromboembolism
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Inflammation
1
Immune System Diseases
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gallbladder Neoplasms
1
Esophageal Neoplasms
1
Dyskinesias
1
Duodenal Neoplasms
1
Cholangiocarcinoma
1
Cardiovascular Diseases
1
Breast Neoplasms
1
Biliary Tract Neoplasms
1
Interventions
Oxaliplatin
81
S 1 (combination)
55
Capecitabine
44
apatinib
32
Paclitaxel
32
Docetaxel
32
Irinotecan
27
Fluorouracil
22
Drug Therapy
21
sintilimab
20
Cisplatin
20
Leucovorin
16
Hyperthermic Intraperitoneal Chemotherapy
13
XELOX
12
Surgical Procedures, Operative
12
camrelizumab
10
Trastuzumab
10
titanium silicide
9
Tegafur
9
Nivolumab
9
Neoadjuvant Therapy
9
pembrolizumab
8
Laparoscopy
8
Gastrectomy
8
Folfox protocol
7
Chemotherapy, Adjuvant
7
toripalimab
6
tislelizumab
6
Ramucirumab
6
Gastroscopy
6
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Stomach Neoplasms
×
Rivaroxaban
×
Clear all
NCT03139487
2020-01-06
PRIORITY
Asan Medical Center
Phase 2
Unknown
176 enrolled